D.E. Shaw & Co
EVLO

D.E. Shaw & Co’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

D.E. Shaw & Co’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-960
Closed -$41K – 5685
2022
Q2 		$41K Sell
960
-187
-16% -$8.67K ﹤0.01% 4878
2022
Q1 		$78K Buy
+1,147
New +$95.5K ﹤0.01% 5049
2021
Q3 		– Sell
-1,689
Closed -$464K – 5370
2021
Q2 		$464K Buy
+1,689
New +$426K ﹤0.01% 4073

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's EVLO Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2022, closing a stake of 960 shares — an estimated $41K sold.

D.E. Shaw & Co first reported a position in EVLO in Q2 2021 and held it in 3 quarters. The position peaked at $464K in Q2 2021. 41 funds tracked by Wall St. Rank hold EVLO as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 960 Evelo Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $41K.
  • D.E. Shaw & Co first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Evelo Biosciences, Inc. Common Stock position peaked at $464K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.